Goldman Sachs Initiates Coverage on Momenta Pharmaceuticals to Neutral

Goldman Sachs Initiates Coverage on Momenta Pharmaceuticals(NASDAQ:MNTA). The shares have been rated Neutral. The rating by Goldman Sachs was issued on Jun 6, 2016.

In a different note, On May 4, 2016, Leerink Swann said it Maintains its rating on Momenta Pharmaceuticals. In the research note, the firm Lowers the price-target to $21.00 per share. The shares have been rated ‘Outperform’ by the firm.

Momenta Pharmaceuticals (MNTA) shares turned negative on Fridays trading session with the shares closing down -0.13 points or -1.10% at a volume of 4,06,533. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.885. The peak price level was also seen at $11.885 while the days lowest was $11.39. Finally the shares closed at $11.67. The 52-week high of the shares is $25.56 while the 52-week low is $7.86. According to the latest information available, the market cap of the company is $811 M.

Momenta Pharmaceuticals(MNTA) last announced its earnings results on May 3, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $19.85M. Analysts had an estimated revenue of $28.12M. Earnings per share were $-0.35. Analysts had estimated an EPS of $-0.32.

Several Insider Transactions has been reported to the SEC. On May 23, 2016, Craig A Wheeler (President) sold 5,880 shares at $10.18 per share price.Also, On May 23, 2016, Bruce Leicher (SVP & General Counsel) sold 1,000 shares at $10.40 per share price.On May 23, 2016, James M. Roach (Senior VP, Development and Chi) sold 1,092 shares at $10.17 per share price, according to the Form-4 filing with the securities and exchange commission.

Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Company’s product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *